GSK1349572 sodium salt CAS No.1051375-19-9 / Cat No.EBD2207054
2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide,N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, sodium salt
2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide,N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, sodium salt
GSK1349572 sodium salt
Dolutegravir sodium salt
2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, sodium salt
Dolutegravir sodium
NMR Spectrum
Prediction： 1 H-NMR spectrum is Figure 19. The signals are summarized below (*= signals of 1 ,2-PG; **=signals of Dolutegravir ): 0.98 (d, J=1.00 Hz, 3 H)*; 1.23 (d, J=7.04 Hz, 3 H)**; 1.37 (d, J=l 1.34 Hz, 1 H)**; 1.79 -1.91 (m, 1 H)**; 2.48 (dt, J=3.62, 1.91 Hz, 7 H) (DMSO); 3.09 - 3.18 (m, 1 H)**; 3.19 - 3.27 (m, 1 H)*; 3.30 (Water); 3.50 - 3.57 (m, 1 H)*; 3.75 - 3.83 (m, 1 H)**; 3.91 - 3.99 (m, 1 H)**; 4.14 (m, J=13.88, 4.89 Hz, 1 H)**; 4.28 (m, J=13.69, 3.13 Hz, 1 H)**; 4.35 - 4.38 (m, 1 H)*; 4.40 - 4.45 (m, 1 H)*; 4.47 - 4.52 (m, 2 H)**; 4.79 (m, J=5.87, 5.87 Hz, 1 H)**; 5.15 (m, J-4.1 1 , 4.1 1 Hz, 1 H)**; 7.01 (m, J=8.36, 8.36 Hz, 1 H)**; 7.19 (m, J=10.46, 9.48, 2.74 Hz, 1 (0269) H)**; 7.34 (m, J=8.70, 8.70, 6.84 Hz, 1 H)**; 7.85 (s, 1 H)**; 10.72 (t, J=5.87 Hz, 1 H)**. The integration values of the methyl groups from DTG-Na (1.23 ppm) and 1 ,2-PG (0.98 ppm) were 3.08 and 3.07
1H NMR
13C NMR
